Can medication efficacy be predicted in schizophrenia patients?
This question is the focus of an international research consortium (CRESTAR), in collaboration with scientists from the CIMH. Among others the researchers aimed to elucidate whether medication efficacy in schizophrenia can be predicted by attributes that can be assessed prior to treatment initiation. First results indicate that medication will be less effective in patients who carry more risk genes for schizophrenia. The study has now been published in the scientific journal Molecular Psychiatry.
Schizophrenia is a major psychiatric disorder, often characterized by a chronic progression in symptoms. This in turn leads to pronounced psychosocial impairment and the requirement for permanent care.
At present, psychiatrists are unable to predict which medication will be effective in a given schizophrenia patient.
The EU-funded CRESTAR project (http://www.crestar-project.eu) aims to investigate this research topic. A particular focus of its research work is a highly potent antipsychotic medication, Clozapine, which has been available since decades. Clozapine however, is only used after at least two trials of other medications have proven to be unsuccessful, as in a small number of cases life-threatening side-effects arise. This approach leads to a delay in effective treatment and a worsening of long-term prognosis.
The CRESTAR researchers are now investigating: First, whether clear indicators for the development of these adverse effects can be identified at an earlier time-point; and second whether clozapine will be effective in a given individual patient. Identification of these factors would allow the safe and effective initiation of clozapine during the early stages of illness.
CRESTAR researchers used information concerning many thousands of genetic markers to show that antipsychotic medication in general will be less effective in patients with a higher genetic load for schizophrenia. This genetic load is already present at birth. Despite the existence of familial schizophrenia, most schizophrenia patients have no family history of the disease. Thus a genetic test to determine the genetic load would represent a first step towards individualized therapy.
Until present psychiatric genetic research has generated few results of direct relevance to treatment, and individual prediction is still not possible. The results of the present study are only a small step into this direction. According to the first author of this recent CRESTAR study, Josef Frank, this is likely to change in the future, since through the development of new biostatistical methods, an increasing amount of information is being obtained concerning genetic variation across the whole genome.
Identification of increased genetic risk scores for schizophrenia in treatment resistant patients.
Josef Frank, Maren Lang, Stephanie H Witt, Jana Strohmaier, Dan Rujescu, Sven Cichon, Franziska Degenhardt, Markus M Nöthen, David A Collier, Stephan Ripke, Dieter Naber & Marcella Rietschel. Molecular Psychiatry (2014). doi:10.1038/mp.2014.56
Contact at the CIMH:
Prof. Dr. Marcella Rietschel
Central Institute of Mental Health
Department of Genetic Epidemiology in Psychiatry
Sigrid Wolff | idw - Informationsdienst Wissenschaft
NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases
Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences
Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...
On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...
The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...
At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.
When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...
At the ILA Berlin, hall 4, booth 202, Fraunhofer FHR will present two radar sensors for navigation support of drones. The sensors are valuable components in the implementation of autonomous flying drones: they function as obstacle detectors to prevent collisions. Radar sensors also operate reliably in restricted visibility, e.g. in foggy or dusty conditions. Due to their ability to measure distances with high precision, the radar sensors can also be used as altimeters when other sources of information such as barometers or GPS are not available or cannot operate optimally.
Drones play an increasingly important role in the area of logistics and services. Well-known logistic companies place great hope in these compact, aerial...
16.03.2018 | Event News
13.03.2018 | Event News
08.03.2018 | Event News
16.03.2018 | Earth Sciences
16.03.2018 | Physics and Astronomy
16.03.2018 | Life Sciences